Pharmaceuticals News and Research

RSS

Barr Pharmaceuticals announces favorable ruling in Yasmin patent case

Barr Pharmaceuticals, Inc. has announced that the U.S. District Court for the District of New Jersey has ruled in favor of its subsidiary, Barr Laboratories, Inc., in the challenge of the patent listed by Bayer Schering Pharma, AG in connection with Bayer Schering's Yasmin(R) (drospirenone and ethinyl estradiol) oral contraceptive.

4 Mar 2008

FDA grants priority review for ACIPHEX (rabeprazole sodium) sNDA for treatment of GERD in adolescents

Eisai Corporation of North America, a wholly-owned subsidiary of Tokyo-based Eisai Co., Ltd., has announced that the Food and Drug Administration (FDA) has accepted an ACIPHEX supplemental New Drug Application (sNDA) for the short-term (up to eight weeks) treatment of gastroesophageal reflux disease (GERD) in patients ages 12-16.

3 Mar 2008

FDA approves PRISTIQ for the treatment of adult patients with major depressive disorder

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the U.S. Food and Drug Administration (FDA) has approved PRISTIQ (desvenlafaxine), a structurally novel, once-daily serotonin-norepinephrine reuptake inhibitor (SNRI), to treat adult patients with major depressive disorder (MDD).

3 Mar 2008

Arsenic used to label antibodies for the detection of tumors

Arsenic linked to a drug that binds to the blood vessels of cancerous tumors provides a powerful imaging agent that could one day allow physicians to detect hard-to-find tumors and more closely monitor cancer's response to therapy, researchers at UT Southwestern Medical Center have found.

3 Mar 2008

Discovery of key molecular mechanism that may account for the development of cystic fibrosis

Researchers from the University of North Carolina at Chapel Hill have identified a key molecular mechanism that may account for the development of cystic fibrosis, which about 1 in 3000 children are born with in the US every year.

1 Mar 2008

Abilify (aripiprazole) approved for acute treatment of bipolar I disorder in adolescents

Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old).

1 Mar 2008

Potential target to treat deadly bloodstream infections

Researchers at the University of Illinois at Chicago have discovered a possible target to treat bloodstream bacterial infections.

28 Feb 2008

Forest Laboratories to develop and distribute the novel beta blocker Bystolic (nebivolol)

Mylan Inc. has announced that it and Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. have amended their January 2006 agreement to commercialize, develop and distribute the novel beta blocker Bystolic (nebivolol), which is currently approved in the United States for the treatment of hypertension.

28 Feb 2008

Chewing gum helps recovery from gastrointestinal surgery

In an article recently recommended by Bradley Kropp of Faculty of 1000 Medicine, researchers find chewing gum is a simple solution to the recovery of bowel function after gastrointestinal surgery – a problem that has troubled patients and physicians for decades.

28 Feb 2008

RFID technology to secure donor blood supply

Radio frequency identification technology, or RFID, has inspired many novel applications of late, including efforts to study magazine reader patterns, access restricted areas, locate stolen vehicles and track luggage at major airports.

27 Feb 2008

Nasal vaccine for smallpox protects animals against 77 times the potentially lethal dose of smallpox

Scientists at NanoBio Corporation and the University of Michigan have demonstrated their nasally delivered vaccinia vaccine can protect animals against 77 times the potentially lethal dose of smallpox, and without the safety risks of current vaccines for smallpox.

27 Feb 2008

Galderma to acquire CollaGenex Pharmaceuticals

Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, and CollaGenex Pharmaceuticals, Inc. has announced a definitive agreement pursuant to which Galderma's U.S. holding company, Galderma Laboratories, Inc., will acquire all of the outstanding shares of CollaGenex at a price of $16.60 per share in cash, representing approximately $420 million for the equity of CollaGenex.

27 Feb 2008

Drug for anemic cancer patients raises risk of death

Millions of cancer patients take drugs to boost their red blood cells and health when they become anemic after chemotherapy.

27 Feb 2008

Barr confirms Avodart patent challenge

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by GlaxoSmithKline in connection with its Avodart(R) (dutasteride) soft gelatin capsules, 0.5mg.

27 Feb 2008

PolyTherics and Celtic Pharma sign agreement to explore technologies for improved drug performance

PolyTherics Limited, a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy, and Celtic Pharma Development Services Bermuda Ltd, a subsidiary of Celtic Pharmaceutical Holdings LP, a global private equity investment fund focused on the biopharma industry, today announced that they have entered into a broad research collaboration agreement.

26 Feb 2008

Mechanism of blood clot elasticity revealed in high definition

Blood clots can save lives, staunching blood loss after injury, but they can also kill. Let loose in the bloodstream, a clot can cause a heart attack, stroke or pulmonary embolism.

26 Feb 2008

Many stroke, heart attack patients may not benefit from aspirin

Up to 20 percent of patients taking aspirin to lower the risk of suffering a second cerebrovascular event do not have an antiplatelet response from aspirin, the effect thought to produce the protective effect, researchers at the University at Buffalo have shown.

26 Feb 2008

Abbott receives approval for HUMIRA (Adalimumab) for polyarticular juvenile idiopathic arthritis

Abbott has announced that it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.

26 Feb 2008

SSRI anti-depressants found to offer little clinical benefit

According to new research from Britain, new generation anti-depressants could be for many patients a waste of time and money and offer little clinical benefit.

26 Feb 2008

Small protein discovered that specifically recognizes tumors responding to chemotherapy

A technique that specifically "tags" tumors responding to chemotherapy may offer a new strategy for determining a cancer treatment's effectiveness within days of starting treatment, according to a new study by Vanderbilt-Ingram Cancer Center investigators.

26 Feb 2008

Pharmaceuticals News and Research

Barr Pharmaceuticals announces favorable ruling in Yasmin patent case

FDA grants priority review for ACIPHEX (rabeprazole sodium) sNDA for treatment of GERD in adolescents

FDA approves PRISTIQ for the treatment of adult patients with major depressive disorder

Arsenic used to label antibodies for the detection of tumors

Discovery of key molecular mechanism that may account for the development of cystic fibrosis

Abilify (aripiprazole) approved for acute treatment of bipolar I disorder in adolescents

Potential target to treat deadly bloodstream infections

Forest Laboratories to develop and distribute the novel beta blocker Bystolic (nebivolol)

Chewing gum helps recovery from gastrointestinal surgery

RFID technology to secure donor blood supply

Nasal vaccine for smallpox protects animals against 77 times the potentially lethal dose of smallpox

Galderma to acquire CollaGenex Pharmaceuticals

Drug for anemic cancer patients raises risk of death

Barr confirms Avodart patent challenge

PolyTherics and Celtic Pharma sign agreement to explore technologies for improved drug performance

Mechanism of blood clot elasticity revealed in high definition

Many stroke, heart attack patients may not benefit from aspirin

Abbott receives approval for HUMIRA (Adalimumab) for polyarticular juvenile idiopathic arthritis

SSRI anti-depressants found to offer little clinical benefit

Small protein discovered that specifically recognizes tumors responding to chemotherapy

Event guide: World ADC San Diego eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring